About | Free Trial

Last Update

2015-06-10T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong A.P. Pharma?

A.P. Pharma

Chief Commercial Officer

A.P. Pharma Inc

HQ Phone: (650) 366-2626

A.P. Pharma Inc

123 Saginaw Drive 123 Saginaw Drive

Redwood City, California 94063

United States

Company Description

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company�s primary focus is on its lead product candidate, APF530, which is being de ... more

Find other employees at this company (33)

Background Information

Employment History

President and Chief Executive Officer
Biotechnology Industry Organization

Chief Commercial Officer
Northwest Biotherapeutics Inc

Global Head Of Oncology
Bayer HealthCare AG

President
PreScience Labs LLC

Vice President Clinical Development, Actelion Pharmaceuticals, Senior Vice President Medical
J. Robert Scott

Vice President of Clinical Development, Vice President of Clinical Development
Financial News

Corporate Controller of The Cooper Companies, Vice President, Finance and Administration
CooperVision Inc

Affiliations

Board Member
Heron Therapeutics Inc

Board Member
CCBN.com Inc

Founder
Prescription Drug User Fee Act

Web References (200 Total References)


A.P. Pharma: Management Change is a Positive for the Stock (APPA.OB, $0.39) | Expert Financial Analysis and Reporting | Smith on Stocks

smithonstocks.com [cached]

A.P. Pharma: Management Change is a Positive for the Stock (APPA.OB, $0.39) | Read more… | See my recent blog A.P. Pharma: Management Change is a Positive for the Stock (APPA.OB, $0.39) | Expert Financial Analysis and Reporting | Smith on Stocks SmithOnStocks Logo

...
A.P. Pharma: Management Change is a Positive for the Stock (APPA.OB, $0.39)
...
The Board of Directors of A.P. Pharma (APPA.OB) has brought in the management team that was responsible for founding the biotechnology company Ardea in 2006 and selling it to Astra Zeneca in April 2012 for $1.3 billion.
...
Robert Rosen, who joined A.P. Pharma in October 2012 as Chief Commercial Officer, will be promoted to the role of President.
...
On the third and final point, A.P. Pharma was unlucky as after submitted its NDA, there was a change in definition in what constituted moderate emetogenic chemotherapy or MEC and what constituted highly emetogenic chemotherapy or HEC.
...
This was a great decision in that A.P. Pharma will probably not be forced to do a new financing at current depressed prices. My analysis suggests that the Company will have about $30 million at the end of 2013. I think that the Company will probably need to raise capital after the approval of APF 530, although perhaps not immediately. I would also point out that new management chose to sell Ardea before it commercialized its lead drug lesinurad and there is a possibility that A.P. Pharma could be sold prior to commercialization of APF 530.
...
A.P. Pharma. APF530 (4)


Heron Therapeutics • Investor Relations • News Release

phx.corporate-ir.net [cached]

A.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3 Antagonist Using APF530 Provides Better Emetic Control Heron Therapeutics • Investor Relations • News Release Heron Therapeutics

...
A.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3 Antagonist Using APF530 Provides Better Emetic Control
...
A.P. Pharma's
...
A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company's primary focus is on its lead product, APF530, for the prevention of CINV. A.P. Pharma


Heron Therapeutics • Board of Directors

www.appharma.com [cached]

Stephen R. Davis joined A.P. Pharma as Executive Vice President and Chief Operating Officer in May 2013 and has served as a member of our board of directors since June 2012.

...
Barry D. Quart, Pharm.D. joined A.P. Pharma in May 2013 as Chief Executive Officer and has served as a member of our board of directors since June 2012.
...
Robert Rosen joined A.P. Pharma as Senior Vice President and Chief Commercial Officer in October 2012 and was appointed to President in May 2013.
...
Prior to joining A.P, Pharma, he served as global head of oncology at Bayer HealthCare, where he was responsible for the development of the global oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific from 2005 to 2011. During his tenure at Bayer Healthcare, he led the launch of Nexavar for the treatment of renal cell carcinoma and hepatocellular carcinoma. Nexavar's worldwide sales in 2011 were $1.0 billion. He also led premarket activities for Stivarga for gastrointestinal stromal tumors and colon cancer and alpharadin for prostate cancer.


A.P. Pharma Inc. • Investor Relations • News Release

phx.corporate-ir.net [cached]

A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress

...
A.P. Pharma
...
A.P. Pharma's
...
A.P. Pharma
A.P. Pharma


Heron Therapeutics • Investor Relations • News Release

phx.corporate-ir.net [cached]

A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress Heron Therapeutics • Investor Relations • News Release Heron Therapeutics

...
A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate Progress
...
A.P. Pharma
...
A.P. Pharma's
...
A.P. Pharma
A.P. Pharma

Similar Profiles

Other People with this Name

Other people with the name Pharma

Ariana Pharma
Ariana Pharma SA

Verona Pharma
Chroma Therapeutics Ltd

Pherecydes Pharma

Amar Pharma
Cachet Pharmaceuticals Pvt. Ltd

Dano Pharma
Danopharm Chemicals

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory